| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785456 | Brachytherapy | 2017 | 6 Pages |
Abstract
HDR-BT yields similar results to low dose rate in treatment of patients with LATC, with better results than those reported with exclusive EBRT. HDR-BT allows to increase the local dose, with good LC rates. In patients with large tumors requiring very mutilating surgery and patients who refuse surgery, EBRT with HDR-BT boost is a good option to increase the LC and cause-specific survival while keeping a better functional outcome.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Miguel Angel Santos, Jose Luis Guinot, Maria Isabel Tortajada, Paula SantamarÃa, Valentin Campo, Laura Oliver, Marina Peña, Leoncio Arribas,